Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...
Phase 3 ABTECT-Maintenance will report 44-week efficacy and safety of obefazimod in moderately to severely active UC using a randomized, double-blind, placebo-controlled design. Subset analyses will ...
Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...
Two global randomized phase 3 studies evaluated ritlecitinib 100 mg (n=1567; exploratory 50 mg) and 50 mg (n=607; age ≥12), ...
Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost ...
IL-31 receptor targeting may differentiate nemolizumab by impacting pruritus-driven neuroimmune signaling while also modulating inflammation and epidermal barrier disruption. Correlative analyses ...
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Intralesional BO-112 demonstrated promising clinical and pathological responses in patients with resectable basal cell ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...
ILT7 is selectively expressed on plasmacytoid dendritic cells, and daxdilimab binding is intended to reduce pDCs in tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results